Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 671 to 680 of 864 total matches.
Topical Sertaconazole (Ertaczo) -- Another Azole for Tinea Pedis
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004 (Issue 1185)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis infection. It has been available in Europe for many years.
L-Carnitine
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004 (Issue 1196)
, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University ...
Carnitine is a naturally occurring amino acid derivative essential for transport of long-chain fatty acids into mitochondria. It is advertised on the Internet as a dietary supplement that can promote weight loss, increase energy, enhance athletic performance and slow aging. Levocarnitine (Carnitor - Sigma-Tau) has been FDA approved for oral and parenteral treatment of primary carnitine deficiency since 1986. Products containing levocarnitine and its synthetic derivative acetyl-L-carnitine are available as dietary supplements in the US.
Antiviral KLEENEX
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005 (Issue 1199)
, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University ...
The first commercially available virucidal tissue, KLEENEX Anti-Viral Tissue (Kimberly-Clark), was recently introduced and is being heavily promoted to the general public. Patients may ask healthcare providers about the usefulness of these products. Theoretically, virucidal tissues could interrupt transmission of viral infections by blocking hand contamination and/or small particle aerosols from nose-blowing, sneezing and coughing.
Apomorphine (Apokyn) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005 (Issue 1200)
. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H ...
Apomorphine (Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with advanced Parkinson's disease. It has been available in Europe for many years.
Virtual Colonoscopy
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005 (Issue 1202)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
Currently available techniques for colorectal cancer screening include fecal occult-blood testing, flexible sigmoidoscopy, double contrast barium enema (DCBE) and traditional optical colonoscopy. Optical colonoscopy requires bowel cleansing and sedation, and involves some risk, but is generally accepted as the best available method for detection of lesions and offers the advantage that polyps can be removed when they are identified. A less invasive screening tool, computed tomography (CT) colonography, also known as virtual colonoscopy (VC), offers an additional option.
Two Once-Daily Fixed-Dose NRTI Combinations for HIV
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005 (Issue 1203)
, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University ...
The FDA has approved emtricitabine/tenofovir (Truvada - Gilead) and abacavir/lamivudine (Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for once-daily use in treatment of HIV infection. Two other fixed-dose NRTI combinations were previously approved for twice-daily dosing. Dual NRTI therapy is generally used in either an NNRTI (non-nucleoside reverse transcriptase inhibitor)-based or a PI (protease inhibitor)-based regimen.
ARBs and Myocardial Infarction
The Medical Letter on Drugs and Therapeutics • May 09, 2005 (Issue 1208)
Meinertz, M.D., University Hospital, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F ...
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Picaridin - A New Insect Repellent
The Medical Letter on Drugs and Therapeutics • Jun 06, 2005 (Issue 1210)
, M.D., University Hospital, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle ...
Picaridin (KBR 3023), which has been used as an insect repellent for years in Europe and Australia (Autan Repel, and others), is now available in the US in 7% solution as Cutter Advanced (Spectrum Brands). The US Centers for Disease Control and Prevention (CDC) is recommending it as an alternative to DEET.
Click here to view the free full article.
Click here to view the free full article.
CYP3A and Drug Interactions
The Medical Letter on Drugs and Therapeutics • Jul 04, 2005 (Issue 1212)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.
AmpliChip CYP450 Test
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005 (Issue 1215)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.